| Literature DB >> 27455250 |
Vito Crincoli1, Laura Fatone2, Margherita Fanelli3, Rossana Patricia Rotolo4, Angela Chialà5, Gianfranco Favia6, Giovanni Lapadula7.
Abstract
Scleroderma is a disorder involving oral and facial tissues, with skin hardening, thin lips, deep wrinkles, xerostomia, tongue rigidity, and microstomia. The aim of this study was to investigate the prevalence of oral manifestations and temporomandibular disorders (TMD) in Systemic Sclerosis (SSc) patients compared with healthy people. Eighty patients (6 men, 74 women) fulfilling ACR/EULAR SSc Criteria were enrolled. A randomly selected group of 80 patients, matched by sex and age served as control group. The examination for TMD signs and symptoms was based on the standardized Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) through a questionnaire and clinical examination. SSc patients complained more frequently (78.8%) of oral symptoms (Xerostomia, dysgeusia, dysphagia and stomatodynia) than controls (28.7%) (χ² = 40.23 p = 0.001). TMD symptoms (muscle pain on chewing, difficulty in mouth opening, headaches) were complained by 92.5% of SSc patients and by 76.2% of controls (χ² = 8.012 p = 0.005). At the clinical examination, 85% of SSc patients showed restricted opening versus 20.0% of controls (χ² = 67.77 p = 0.001), 81.2% of SSc showed reduced right lateral excursion versus 50% of controls (χ² = 17.316 p = 0.001); 73.8% of SSc showed limited left lateral excursion versus 53.8% of controls (χ² = 6.924 p = 0.009); and 73.8% of SSc had narrow protrusion versus 56.2% of controls (χ² = 5.385 p = 0.02).Entities:
Keywords: oral manifestation; scleroderma; temporomandibular disorders
Mesh:
Year: 2016 PMID: 27455250 PMCID: PMC4964558 DOI: 10.3390/ijms17071189
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Presence of telangiectasia.
Figure 2SSc patient. Microstomia has been measured as the distance between the lip commissures.
Figure 3Maximum active opening: 19 mm, negative end-feel. Pronounced labial wrinkles, sharp nose.
Sociodemographic characteristics of SSc patients and controls.
| Sociodemographic Characteristics | SSc | Controls | Test | |
|---|---|---|---|---|
| Age, mean ± SD | 56.28 ± 12.96 | 56.45 ± 13.05 | ||
| Sex, | ||||
| male | 6 (7.5%) | 6 (7.5%) | ||
| female | 74 (92.5%) | 74 (92.5%) | ||
| Educational degree, | ||||
| primary | 17 (21.2%) | 9 (11.2%) | χ2 = 6.691 | 0.082 |
| secondary | 26 (32.5%) | 19 (23.8%) | ||
| high | 31 (38.8%) | 40 (50%) | ||
| academic | 6 (7.5%) | 12 (15%) | ||
| Occupation, | ||||
| housewife | 31 (38.8%) | 24 (30%) | χ2 = 11.036 | 0.026 |
| retired | 22 (27.5%) | 18 (22.5%) | ||
| office worker | 19 (23.8%) | 34 (42.5%) | ||
| self employed | 1 (1.2%) | 3 (3.8%) | ||
| not employed | 7 (8.7%) | 1 (1.2%) | ||
| Marital status, | ||||
| married | 56 (70%) | 63 (78.7%) | χ2 = 5.271 | 0.153 |
| widower | 5 (6.2%) | 8 (10%) | ||
| single | 17 (21.3%) | 7 (8.8%) | ||
| divorced | 2 (2.5%) | 2 (2.5%) |
Form of disease of SSc patients.
| Form of Disease | Type of SSc, | Mean ± SD (Range) | |
|---|---|---|---|
| Diffuse | 66 (82.5%) | - | |
| Limited | 14 (17.5%) | - | |
| Age at diagnosis | - | 44 ± 14.24 (8–74) | |
| Disease duration (class of years) | <5 years | 21 (26.2%) | - |
| 5–10 years | 11 (13.8%) | - | |
| >10 years | 48 (60%) | - | |
| Disease duration | - | 12 ± 8.39 (1–50) | |
Clinical characteristics of SSc patients and controls.
| Clinical Characteristics | SSc | Controls | Test | |
|---|---|---|---|---|
| Cardiopathy | 24 (30%) | 3 (3.8%) | χ2 = 19.649 | <0.001 |
| Diabetes mellitus | 5 (6.2%) | 1 (1.2%) | χ2 = 2.771 | 0.096 |
| Digital ulcers | 16 (20%) | 0 | Fisher exact test | <0.001 |
| Esophageal disease | 26 (32.5%) | 2 (2.5%) | χ2 = 2..935 | <0.001 |
| Gastritis | 6 (7.5%) | 2 (2.5%) | χ2 = 2.105 | 0.147 |
| Hypertyension | 9 (11.2%) | 16 (20%) | χ2 = 2.323 | 0.127 |
| Hypovitaminosis | 11 (13.8%) | 2 (2.5%) | χ2 = 6.782 | 0.009 |
| Interstitial lung disease | 27 (33.8%) | 0 | Fisher exact test | <0.001 |
| Osteoporosis | 19 (23.8%) | 1 (1.2%) | Fisher exact test | <0.001 |
| Presence of removable prosthesis | 10 (12.5%) | 15 (18.8%) | χ2 = 1.185 | 0.276 |
| Raynaud syndrome | 45 (56.2%) | 0 | Fisher exact test | <0.001 |
| Thyroid disease | 16 (20%) | 14 (17.5%) | χ2 = 0.164 | 0.685 |
SSc patients and controls’ drugs.
| Drugs | SSc | Controls | Test | |
|---|---|---|---|---|
| ACE inhibitors | 7 (9.2%) | 2 (2.5%) | χ2 = 2.112 | 0.146 |
| Acetylsalicylic acid | 19 (25%) | 3 (3.8%) | χ2 = 14.528 | <0.001 |
| Angiotensin II receptor antagonist | 5 (6.6%) | 0 | Fisher exact test | 0.026 |
| Antacids | 57 (75%) | 4 (5%) | χ2 = 80.199 | <0.001 |
| Beta blockers | 4 (5.3%) | 19 (23.8%) | χ2 = 10.597 | 0.001 |
| Bisphosphonate | 13 (17.1%) | 1 | Fisher exact test | <0.001 |
| Calcium channel blockers | 34 (44.7%) | 1 (1.2%) | Fisher exact test | <0.001 |
| Cholecalciferol | 43 (56.6%) | 4 (5%) | Fisher exact test | <0.001 |
| Digitalis glycosides | 2 (2.6%) | 0 | Fisher exact test | 0.236 |
| Diuretics | 14 (18.4%) | 4 (5%) | χ2 = 6.89 | 0.009 |
| Endothelin receptor antagonists | 39 (51.3%) | 0 | Fisher exact test | <0.001 |
| Iloprost | 71 (88.8%) | 0 | Fisher exact test | <0.001 |
| Immunosuppressant | 41 (53.9%) | 0 | Fisher exact test | <0.001 |
| Lipid-lowering drugs | 11 (14.5%) | 10 (12.5%) | χ2 = 0.130 | 0.718 |
| Nitrate drugs | 4 (5.3%) | 0 | Fisher exact test | <0.001 |
| Nonsteroidal anti-inflammatory drugs | 4 (5.3%) | 0 | Fisher exact test | 0.054 |
| Prokinetic drugs | 35 (46.1%) | 0 | Fisher exact test | <0.001 |
| Thyroxine | 10 (13.2%) | 15 (18.8%) | χ2 = 0.906 | 0.341 |
| Ursodeoxycholic acid | 9 (11.8%) | 0 | Fisher exact test | 0.001 |
Subjective complaints of oral discomfort in SSC patients and controls.
| Oral Symptoms | SSc | Controls | χ2 | |
|---|---|---|---|---|
| Xerostomia | 42 (52.5%) | 17 (21.3%) | 16.78 | <0.001 |
| Dysgeusia | 27 (33.8%) | 4 (5.0%) | 19.36 | <0.001 |
| Dysphagia | 41 (51.3%) | 3 (3.8%) | 42.91 | <0.001 |
| Stomatodynia | 23 (28.8%) | 4 (5.0%) | 14.44 | <0.001 |
Myofascial pain in SSC patients and controls.
| Muscle | SSc | Controls | χ2 | |
|---|---|---|---|---|
| Anterior temporalis muscles | 36 (45.0%) | 18 (22.5%) | 9.06 | 0.003 |
| Medial temporalis muscles | 32 (40.0%) | 16 (20.0%) | 7.62 | 0.006 |
| Posterior temporalis muscles | 25 (31.3%) | 12 (15.0%) | 5.94 | 0.015 |
| Superficial masseter muscles | 58 (72.5%) | 37 (46.3%) | 11.43 | 0.001 |
| Deep masseter muscles | 59 (73.8%) | 36 (45.0%) | 13.71 | <0.001 |
| Medial pterygoid muscles | 42 (52.5%) | 40 (50.0% | 0.1 | 0.752 |
| Lateral pterygoid muscle | 64 (80.0%) | 53 (66.3%) | 3.85 | 0.05 |
| Digastric muscle—anterior belly | 19 (23.8%) | 4 (5.0%) | 9.95 | 0.002 |
| Digastric muscle—posterior belly | 24 (30.0%) | 3 (3.8%) | 17.82 | <0.001 |
| Mylohyoid muscles | 14 (17.7%) | 5 (6.3%) | 4.97 | 0.026 |
| Sternocleidomastoid muscles—sternal head | 60 (75.0%) | 62 (77.5%) | 0.138 | 0.71 |
| Sternocleidomastoid muscles—clavicular head | 53 (66.3%) | 56 (70.0%) | 0.259 | 0.611 |
Oral signs for SScs and controls.
| Oral Signs | SSc | Controls | χ2 | |
|---|---|---|---|---|
| Microstomia | 64 (80%) | 2 (2.5%) | 95.96 | <0.001 |
| Oral ulcers | 31 (38.8%) | 9 (11.3%) | 16.13 | <0.001 |
| Petechiae | 18 (22.5%) | 0 (0.0%) | 18.09 | <0.001 |
| Gingival recession | 56 (70.0%) | 26 (32.5%) | 22.51 | <0.001 |
| erythematous tongue | 37 (46.3%) | 3 (3.8%) | 38.53 | <0.001 |
| Fibrous tongue | 21 (26.3%) | 13 (16.3%) | 2.39 | 0.122 |
Restricted Movements (RM).
| Measurements (mm); Mean ± SD | SSc | Controls | ||
|---|---|---|---|---|
| Opening | 33.29 ± 7.97 | 43.37 ± 6.64 | −8.693 | <0.001 |
| Laterotrusion right | 5.67 ± 3.14 | 7.3 ± 2.5 | −3.622 | <0.001 |
| Laterotrusion left | 5.87 ± 3.61 | 7.37 ±2.48 | −3.059 | 0.009 |
| Protrusion | 4.62 ± 3.28 | 6.17 ± 2.6 | −3.313 | 0.02 |